Experts regret early cessation of anticancer drug trialBMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7420.885 (Published 16 October 2003) Cite this as: BMJ 2003;327:885
- Scott Gottlieb
- New York
Treatment with the aromatase inhibitor letrozole after five years of tamoxifen treatment seems to improve disease-free survival in postmenopausal women with primary breast cancer.
The study, designed to test five years of letrozole treatment after tamoxifen therapy, was discontinued after a median follow up of only 2.4 years because the researchers observed survival benefit in the letrozole group compared with the placebo group. The study is scheduled to …